Author(s)

Miguel Jiménez-Pérez, Francisco Javier Rando-Muñoz, Rocío González-Grande, Fernando González-Panizo Tamargo, Jesús de la Cruz Lombardo, Juan Miguel Rodrigo López, Román Manteca González

Department of Gastroenterology and Hepatology, Liver Transplantation Unit, University Hospital Carlos Haya, Málaga, Spain.

The recurrence of hepatitis C after a liver transplant remains an important cause of graft loss and retransplant. Antiviral therapy with peginterferon plus ribavirin (PEG-INF/RBV) can achieve a sustained viral response and histological improvement in a high percentage of cases. However, this treatment is not exempt from important side effects or from the possibility of precipitating rejection, with the resulting graft loss. We report the case of a liver transplant patient who received treatment with PEG-INF/RBV and developed plasma cell hepatitis as the presenting form of rejection.

 

Liver Transplantation; C Hepatitis Treatment; Plasmatic Cells; Allograft Rejection; Autoinmune Response

Jiménez-Pérez, M. , Rando-Muñoz, F. , González-Grande, R. , Tamargo, F. , de la Cruz Lombardo, J. , López, J. and González, R. (2013) Post-transplant plasma cell hepatitis in a liver transplant patient treated with pegylated interferon plus ribavirin. Open Journal of Gastroenterology, 3, 307-310. doi: 10.4236/ojgas.2013.37053.